Which of these prescription medications are YOU taking?
Most people are aware that antibiotic medications can alter the balance of good and bad bacteria in the gut. In addition to the science we have proving this, many of us have personally experienced upset bellies and changes in stool patterns upon taking an antibiotic.
However, many people do not know that many other categories of commonly prescribed drugs – not just antibiotics – can also alter our microbial health. This includes medications that have therapeutic effects directed at the gastrointestinal tract such as proton pump inhibitors, as well as anti-diabetic medications, statins, antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), and atypical antipsychotics. Many patients use these types of medications on an ongoing basis. With our increasing knowledge of how our gut microbiome affects our mood, metabolism, immune system function and more,, it is imperative that we look further at how we are altering its normal balance, as well as if supportive strategies such as probiotics should be inherently recommended when we elect to use these additional types of medications, especially long-term.
Proton pump inhibitors
Although antibiotics are often blamed for the increased incidence of Clostridium difficile, a bacteria that can cause a life-threatening infection in the intestines, the use of proton pump inhibitors (PPIs) also is a contributing factor. Multiple systemic reviews have shown an association between the use of medications that suppress stomach acid production and increased risk of gastrointestinal infections., PPIs are among the most common prescriptions in the world, including in children., By reducing stomach acid production, PPIs allow for the survival of harmful bacteria that otherwise would not survive the harsh acidic environment of the stomach. Users of PPIs have also been shown to have a significantly different composition of microbes in the gut than non-PPI users.
Interestingly, probiotics have been shown to significantly reduce the incidence of colic and reflux in infants, as well as upper gastrointestinal symptoms like reflux in adults,, leading many integrative practitioners to use this as an adjunctive or alternative first-line intervention.
Metformin is recommended as the first-line intervention for patients newly diagnosed with type 2 diabetes mellitus (T2DM), or insulin-resistant diabetes. As approximately 10 to 15% of the US population has T2DM, the number of individuals using this medication, at least during some period of the course of this often-chronic illness, is almost as high as the prevalence of the disease itself. Metformin has been demonstrated to inhibit the growth of Bifidobacterium longum, a “good” type of bacteria commonly found at high numbers in the human gut. Treatment of T2DM with metformin has also been shown to lead to a significant increase of Escherichia spp. (like E. coli), as well as other changes to the microbial balance.
Metabolic side effects are commonly associated with the use of atypical antipsychotic medications, but the mechanisms of these changes are largely not understood. In women being treated with these medications, a significantly decreased species diversity of the gut microbiome has been observed. Decreased levels of bacterial species diversity, such as seen here, is one of the things which have been seen with obesity, and may be a contributing factor in this medication-treated group as well.
Click here to see References
 Jackson MA, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016 May;65(5):749-56.
 Forslund K, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015 Dec 10;528(7581):262-266.
 Imhann F, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017 Jul 4;8(4):351-358.
 Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016 Feb;22(2):178.e1-178.e9.
 Flowers SA, et al. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacotherapy. 2017 Mar;37(3):261-267.
 Foster JA, et al. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013 May;36(5):305-12.
 Devaraj S, et al. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013 Apr;59(4):617-28.
 Kau AL, et al. Human nutrition, the gut microbiome and the immune system. Nature. 2011 Jun 15;474(7351):327-36.
 McLoughlin RM, et al. Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. J Allergy Clin Immunol. 2011 May;127(5):1097-107.
 Janarthanan S, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012 Jul;107(7):1001-10.
 Leonard J, et al. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007 Sep;102(9):2047-56
 Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1269-81.
 Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):7-16.
 Nelson SP, et al. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. J Med Econ. 2009;12(4):348-55.
 Rosen R, et al. Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. JAMA Pediatr. 2014 Oct;168(10):932-7.
 Schreck Bird A, et al. Probiotics for the Treatment of Infantile Colic: A Systematic Review. J Pharm Pract. 2017 Jun;30(3):366-374.
 Maier L, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628.
 Arboleya S, et al. Gene-trait matching across the Bifidobacterium longum pan-genome reveals considerable diversity in carbohydrate catabolism among human infant strains. BMC Genomics. 2018 Jan 8;19(1):33.
 Shin NR, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014 May;63(5):727-35.
 Turnbaugh PJ, et al. A core gut microbiome in obese and lean twins. Nature. 2009 Jan 22;457(7228):480-4.